by Jasmine Phiri
May 11, 2020
Senior Vice President, Head of Market Access Value and Evidence Strategy,
Doug Danison joined bluebird bio in July 2015 charged with establishing the global pricing, market access, and health economics team known as Access Value & Evidence Strategy (AVES). As the longest tenured commercial “bird” he leads bluebird’s pricing, market access and value demonstration efforts including direct oversight of the Global, US, and European AVES teams.
During more than 18 years of Pricing & Market Access experience, including roles with Eli Lilly & Company, Amgen, Millennium/Takeda Oncology and now bluebird bio, he has led or overseen the preparation of market access strategies for products in early development, pivotal study planning, launch, and post launch lifecycle management. While addressing market access challenges from a variety of vantage points including Global, European Regional, and US roles he’s built teams, processes, and a knowledgebase that enables the execution of market access strategies which anticipate and meet the needs of access decision makers in an increasing challenging market access environment.